CL2013000586A1 - Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. - Google Patents

Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.

Info

Publication number: CL2013000586A1
Authority: CL; Chile
Prior art keywords: tgf; patient; procedure; reducing; myocardial infarction
Prior art date: 2010-09-01

Application number

CL2013000586A

Other languages

English (en)

Inventor

Geoffrey Y Akita

Scott Lonning

Richard C Gregory Jr

Amelia B Kudej

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-09-01

Filing date

2013-02-28

Publication date

2013-08-30

2013-02-28 Application filed by Genzyme Corp filed Critical Genzyme Corp

2013-08-30 Publication of CL2013000586A1 publication Critical patent/CL2013000586A1/es

Links

230000002411 adverse Effects 0.000 title 1
239000002876 beta blocker Substances 0.000 title 1
208000010125 myocardial infarction Diseases 0.000 title 1
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Genetics & Genomics (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cell Biology (AREA)
Diabetes (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Rheumatology (AREA)
Analytical Chemistry (AREA)

CL2013000586A 2010-09-01 2013-02-28 Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta. CL2013000586A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37931510P	2010-09-01	2010-09-01

Publications (1)

Publication Number	Publication Date
CL2013000586A1 true CL2013000586A1 (es)	2013-08-30

Family

ID=44654454

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013000586A CL2013000586A1 (es)	2010-09-01	2013-02-28	Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.

Country Status (19)

Country	Link
US (2)	US20130330352A1 (es)
EP (1)	EP2611831B1 (es)
JP (2)	JP6377348B2 (es)
KR (1)	KR101939965B1 (es)
CN (1)	CN103201292B (es)
BR (1)	BR112013004850B1 (es)
CA (1)	CA2809568C (es)
CL (1)	CL2013000586A1 (es)
ES (1)	ES2715177T3 (es)
IL (1)	IL225018A (es)
MX (1)	MX354535B (es)
MY (1)	MY165160A (es)
NZ (2)	NZ624382A (es)
PH (1)	PH12013500411A1 (es)
PL (1)	PL2611831T3 (es)
RU (1)	RU2637088C2 (es)
SG (2)	SG187953A1 (es)
TR (1)	TR201903101T4 (es)
WO (1)	WO2012030394A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2398502T3 (pl) *	2009-02-18	2016-03-31	Cormatrix Cardiovascular Inc	Kompozycje i sposoby do zapobiegania zaburzeniu rytmu serca
EP3415633B1 (en)	2013-03-11	2020-10-28	Genzyme Corporation	Engineered anti-tgf-beta antibodies and antigen-binding fragments
WO2015027082A1 (en)	2013-08-22	2015-02-26	Acceleron Pharma, Inc.	Tgf-beta receptor type ii variants and uses thereof
WO2016100233A1 (en)	2014-12-15	2016-06-23	The Regents Of The University Of California	Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
SMT202500043T1 (it)	2014-12-15	2025-03-12	Univ California	Recettore antigenico chimerico bispecifico or-gate sensibile a cd19 e cd20
CN108348578B (zh)	2015-08-04	2022-08-09	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
FI3368571T3 (fi) *	2015-10-30	2023-02-28		Transformoivia kasvutekijä-beeta-vasteellisia polypeptidejä ja niiden käyttömenetelmiä
WO2017123550A1 (en) *	2016-01-11	2017-07-20	Autotelic Llc	Composition, device, and method for detecting olmesartan and improving compliance in treating hypertension
US20170218040A1 (en) *	2016-02-02	2017-08-03	Julio A. Camarero Palao	Proteolically resistant cyclotides with angiotensin 1-7 like activity
CA3033614A1 (en) *	2016-08-11	2018-02-15	Precithera, Inc.	Tgf-.beta. antagonist conjugates
PL3628049T3 (pl)	2017-05-04	2023-09-25	Acceleron Pharma Inc.	Białka fuzyjne receptora TGF-beta typu II i ich zastosowania
JPWO2023054712A1 (es)	2021-09-30	2023-04-06

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5571714A (en)	1988-12-22	1996-11-05	Celtrix Pharmaceuticals, Inc.	Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DK1137941T4 (da)	1998-12-10	2014-01-06	Brystol Myers Squibb Company	Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
US7763580B2 (en) *	1999-01-05	2010-07-27	University Of Utah Research Foundation	Methods for treating conditions associated with the accumulation of excess extracellular matrix
MXPA06011199A (es) *	2004-03-31	2007-04-16	Genentech Inc	Anticuerpos anti-tgf-beta humanizados.
JP2008528626A (ja)	2005-01-31	2008-07-31	マイランラボラトリーズインク．	ヒドロキシル化されたネビボロールを含む薬学的組成物
EP1850873B1 (en) *	2005-02-08	2018-11-28	Genzyme Corporation	Antibodies to tgfbeta
CA2747251A1 (en) *	2009-01-26	2010-07-29	Intermune, Inc.	Methods for treating acute myocardial infarctions and associated disorders
ITMI20110376A1 (it)	2011-03-10	2012-09-11	Wilic Sarl	Aerogeneratore raffreddato a fluido

2011
- 2011-09-01 ES ES11758276T patent/ES2715177T3/es active Active
- 2011-09-01 BR BR112013004850A patent/BR112013004850B1/pt not_active IP Right Cessation
- 2011-09-01 MX MX2013002390A patent/MX354535B/es active IP Right Grant
- 2011-09-01 KR KR1020137008326A patent/KR101939965B1/ko not_active Expired - Fee Related
- 2011-09-01 SG SG2013013875A patent/SG187953A1/en unknown
- 2011-09-01 PH PH1/2013/500411A patent/PH12013500411A1/en unknown
- 2011-09-01 NZ NZ624382A patent/NZ624382A/en not_active IP Right Cessation
- 2011-09-01 WO PCT/US2011/001536 patent/WO2012030394A1/en active Application Filing
- 2011-09-01 CN CN201180052346.0A patent/CN103201292B/zh not_active Expired - Fee Related
- 2011-09-01 EP EP11758276.7A patent/EP2611831B1/en active Active
- 2011-09-01 SG SG10201506909PA patent/SG10201506909PA/en unknown
- 2011-09-01 PL PL11758276T patent/PL2611831T3/pl unknown
- 2011-09-01 NZ NZ608813A patent/NZ608813A/en not_active IP Right Cessation
- 2011-09-01 US US13/819,393 patent/US20130330352A1/en not_active Abandoned
- 2011-09-01 MY MYPI2013000675A patent/MY165160A/en unknown
- 2011-09-01 JP JP2013527063A patent/JP6377348B2/ja not_active Expired - Fee Related
- 2011-09-01 CA CA2809568A patent/CA2809568C/en not_active Expired - Fee Related
- 2011-09-01 RU RU2013114365A patent/RU2637088C2/ru active
- 2011-09-01 TR TR2019/03101T patent/TR201903101T4/tr unknown
2013
- 2013-02-28 IL IL225018A patent/IL225018A/en active IP Right Grant
- 2013-02-28 CL CL2013000586A patent/CL2013000586A1/es unknown
2016
- 2016-12-12 US US15/376,358 patent/US10633437B2/en not_active Expired - Fee Related
2017
- 2017-04-20 JP JP2017083499A patent/JP2017193543A/ja active Pending

Also Published As

Publication number	Publication date
US20130330352A1 (en)	2013-12-12
SG10201506909PA (en)	2015-10-29
RU2637088C2 (ru)	2017-11-29
MY165160A (en)	2018-02-28
PL2611831T3 (pl)	2019-05-31
JP6377348B2 (ja)	2018-08-22
IL225018A (en)	2017-11-30
KR20130111550A (ko)	2013-10-10
ES2715177T3 (es)	2019-06-03
KR101939965B1 (ko)	2019-01-18
EP2611831A1 (en)	2013-07-10
CA2809568A1 (en)	2012-03-08
SG187953A1 (en)	2013-03-28
NZ608813A (en)	2014-11-28
US20170233465A1 (en)	2017-08-17
CN103201292A (zh)	2013-07-10
JP2017193543A (ja)	2017-10-26
BR112013004850A2 (pt)	2016-05-31
JP2013542179A (ja)	2013-11-21
CA2809568C (en)	2019-06-11
CN103201292B (zh)	2016-09-14
EP2611831B1 (en)	2018-12-12
RU2013114365A (ru)	2014-10-10
US10633437B2 (en)	2020-04-28
PH12013500411A1 (en)	2022-03-30
MX354535B (es)	2018-03-09
AU2011296574A1 (en)	2013-03-21
TR201903101T4 (tr)	2019-03-21
AU2011296574B2 (en)	2015-12-03
WO2012030394A1 (en)	2012-03-08
NZ624382A (en)	2015-05-29
MX2013002390A (es)	2013-08-27
BR112013004850B1 (pt)	2020-04-07

Publication	Publication Date	Title
CL2013000586A1 (es)	2013-08-30	Procedimieno de reduccion de una consecuencia adversa de un infarto de miocardio en un paciente utilizando antagonista de tgf-beta.
NO20210424A1 (no)	2011-08-05	Fremgangsmåte for å utføre brønnoperasjoner
BRPI0910307A2 (pt)	2019-09-24	inibidores de hiv integrase
SMT201500271B (it)	2016-01-08	Inibitori di neprilisina
DK3419208T3 (da)	2021-04-26	Fremgangsmåde til diskontinuerlig modtagelsesdrift for long-term-evolution-advanced-bæreraggregering
CR20120576A (es)	2013-03-04	Inhibidores de pirazolil quinazolina cinasa
ME03376B (me)	2020-01-20	Makrociklička jedinjenja kао inhibiтori trk kinaze
EP2603600A4 (en)	2014-10-29	PEPTIDOMIMETIC MACROCYCLES
FR2971145B1 (fr)	2014-04-25	Implant de corporectomie
LT3023102T (lt)	2018-09-25	Ibat inhibitoriai, skirti kepenų ligų gydymui
CO6781493A2 (es)	2013-10-31	Inhibidores de la faah
IT1394860B1 (it)	2012-07-20	Composti farmaceutici
EP3738544C0 (de)	2023-10-18	Dentalimplantat
DK2496236T3 (da)	2013-07-08	Prolylhydroxylasehæmmere
HRP20161771T1 (hr)	2017-02-24	Formulacije bendamustina
FR2960763B1 (fr)	2013-08-02	Implant de suture
BRPI1008379A2 (pt)	2016-02-23	bateria
CR20140068A (es)	2014-08-18	Una formulación herbicida mejorada
EP2563127A4 (en)	2013-11-06	PROLYLCARBOXYPEPTIDASE INHIBITORS
EP2667410A4 (en)	2017-09-06	Solid-state imaging device
BR112012001026A2 (pt)	2016-03-15	bateria
EP2632895A4 (en)	2015-12-16	INHIBITORS OF HIV PROTEASE
ES2562643T8 (es)	2022-07-12	Conjugado de naloxol-peg cristalino
EP2667589A4 (en)	2017-03-08	Solid-state imaging device
ZA201102620B (en)	2011-12-28	Hiv integrase inhibitors